---
schema_version: "secwatch.filing_event.v1"
accession: "0001730463-24-000004"
form_type: "8-K"
ticker: "AUTL"
cik: "0001730463"
company_name: "Autolus Therapeutics plc"
filed_at: "2024-01-10T23:59:59+00:00"
generated_at: "2026-06-07T00:58:39.457663+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Autolus appoints Robert Azelby to Board, commercial focus as BLA for obe-cel submitted

## Summary
- Robert W. Azelby appointed Class II director effective Jan 9, 2024; brings 30+ years biopharma commercial experience.
- Initial option grant of 80,000 ADSs at $6.84/share; annual retainer £52,500 plus £3,500 for committee service.
- Azelby was CEO of Eliem Therapeutics and Alder BioPharmaceuticals; served at Juno and Amgen.
- Company recently submitted BLA for lead CAR T therapy obe-cel; Azelby to aid commercialization.

## SEC filing metadata
- accession: 0001730463-24-000004
- form_type: 8-K
- ticker: AUTL
- cik: 0001730463
- company_name: Autolus Therapeutics plc
- filed_at: 2024-01-10T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730463/000173046324000004/0001730463-24-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730463/000173046324000004/autl-20240109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001730463-24-000004
- JSON: https://secwatch.observer/filing/0001730463-24-000004.json
- Plain text: https://secwatch.observer/filing/0001730463-24-000004.txt

## Key facts
- Executive change
  Robert W. Azelby was appointed as Class II director at Autolus Therapeutics plc.
  - Action: appointed
  - Role: Class II director
  source text: appointed Robert (“Bob”) W. Azelby to serve as a Class II director of the Company, effective January 9, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1730463/000173046324000004/0001730463-24-000004-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.